Thermo Fisher Scientific Inc. (NYSE:TMO) – Investment analysts at Leerink Swann issued their Q1 2020 earnings per share estimates for shares of Thermo Fisher Scientific in a research report issued to clients and investors on Sunday, June 24th. Leerink Swann analyst P. Souda forecasts that the medical research company will post earnings of $3.09 per share for the quarter.
Thermo Fisher Scientific (NYSE:TMO) last announced its earnings results on Wednesday, April 25th. The medical research company reported $2.50 earnings per share for the quarter, topping analysts’ consensus estimates of $2.42 by $0.08. Thermo Fisher Scientific had a return on equity of 16.09% and a net margin of 10.24%. The firm had revenue of $5.85 billion for the quarter, compared to the consensus estimate of $5.62 billion. During the same quarter in the previous year, the business earned $2.08 EPS. The company’s revenue was up 22.8% compared to the same quarter last year.
A number of other brokerages also recently weighed in on TMO. Morgan Stanley cut their target price on Thermo Fisher Scientific from $228.00 to $216.00 and set an “overweight” rating on the stock in a research note on Wednesday, April 11th. Zacks Investment Research upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating and set a $240.00 price objective on the stock in a research note on Thursday, March 22nd. Finally, ValuEngine downgraded Thermo Fisher Scientific from a “buy” rating to a “hold” rating in a research note on Wednesday, June 20th. Two research analysts have rated the stock with a hold rating and fifteen have assigned a buy rating to the company’s stock. Thermo Fisher Scientific has an average rating of “Buy” and an average price target of $224.38.
Shares of NYSE TMO opened at $204.93 on Tuesday. Thermo Fisher Scientific has a twelve month low of $170.07 and a twelve month high of $226.44. The company has a market capitalization of $83.98 billion, a PE ratio of 21.59, a price-to-earnings-growth ratio of 1.53 and a beta of 1.11. The company has a current ratio of 1.36, a quick ratio of 0.95 and a debt-to-equity ratio of 0.69.
The company also recently disclosed a quarterly dividend, which will be paid on Monday, July 16th. Investors of record on Friday, June 15th will be paid a $0.17 dividend. The ex-dividend date of this dividend is Thursday, June 14th. This represents a $0.68 annualized dividend and a yield of 0.33%. Thermo Fisher Scientific’s payout ratio is 7.17%.
In other Thermo Fisher Scientific news, Director C Martin Harris sold 206 shares of the business’s stock in a transaction on Friday, May 18th. The shares were sold at an average price of $214.43, for a total transaction of $44,172.58. Following the sale, the director now owns 5,106 shares of the company’s stock, valued at approximately $1,094,879.58. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CFO Stephen Williamson sold 2,500 shares of the business’s stock in a transaction on Monday, June 4th. The shares were sold at an average price of $212.00, for a total transaction of $530,000.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 97,706 shares of company stock worth $21,125,673. 0.49% of the stock is owned by company insiders.
Hedge funds have recently modified their holdings of the business. Commerce Bank raised its holdings in Thermo Fisher Scientific by 1.6% during the 4th quarter. Commerce Bank now owns 227,763 shares of the medical research company’s stock valued at $43,248,000 after acquiring an additional 3,577 shares during the period. Lazard Asset Management LLC increased its holdings in shares of Thermo Fisher Scientific by 14.3% in the fourth quarter. Lazard Asset Management LLC now owns 1,225,034 shares of the medical research company’s stock worth $232,608,000 after purchasing an additional 153,707 shares during the period. Edge Advisors LLC increased its holdings in shares of Thermo Fisher Scientific by 5.4% in the fourth quarter. Edge Advisors LLC now owns 5,355 shares of the medical research company’s stock worth $1,016,000 after purchasing an additional 276 shares during the period. Flinton Capital Management LLC increased its holdings in shares of Thermo Fisher Scientific by 1.8% in the fourth quarter. Flinton Capital Management LLC now owns 300,424 shares of the medical research company’s stock worth $57,045,000 after purchasing an additional 5,440 shares during the period. Finally, LPL Financial LLC increased its holdings in shares of Thermo Fisher Scientific by 5.4% in the fourth quarter. LPL Financial LLC now owns 57,216 shares of the medical research company’s stock worth $10,864,000 after purchasing an additional 2,910 shares during the period. 85.76% of the stock is currently owned by institutional investors and hedge funds.
Thermo Fisher Scientific Company Profile
Thermo Fisher Scientific Inc provides analytical instruments, equipment, reagents and consumables, software, and services for research, manufacturing, analysis, discovery, and diagnostics under the Thermo Scientific, Applied Biosystems, Invitrogen, Fisher Scientific, and Unity Lab Services brands worldwide.
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.